Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial-a randomized, double-blinded, placebo-controlled trial
Scope: Comprehensive review of ANGPTL3 inhibition as a therapeutic strategy to reduce triglyceride-rich lipoproteins and residual cardiovascular risk Therapeutic approaches discussed: Monoclonal antibodies (e.g., evinacumab) RNA-based therapies (ASOs and siRNA: vupanorsen, zodasiran, solbinsiran) Emerging gene-editing strategies (CRISPR/base editing) Key message: Targeting ANGPTL3 provides robust reductions in triglycerides, apoB-containing lipoproteins, and non-HDL cholesterol, independently of the LDL receptor Clinical relevance: Positions ANGPTL3 inhibition as a next-generation approach for managing mixed dyslipidemia and lipid-related residual risk beyond LDL-C Laura Schreier Natalia Nardelli European Atherosclerosis Society To view or add a comment, sign in Tipping the Scale in MASH: The TZD vs
It offers the largest surface area for rotation, consistent subcutaneous fat depth, and reliable absorption rates
No Titanium Dioxide Packaging contains recycled content - Bottles are made from 100% post-consumer recycled plastic Join our journey to Zero
Fresh produce, lean proteins, eggs, dairy and healthier grains usually sit on these outer aisles
The orders cover all pending and future New Jersey state court cases against Novo Nordisk and Eli Lilly related to GLP-1 drugs such as Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound
